Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
2,436
Completed, industry sponsors, Cardiovascular and metabolic, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting193
- Completed2,436
2,436 trials
Showing 1 to 25, recently updated first.
- A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini StrokePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05686070 · 12,327 participants · Start Jan 26, 2023 · Primary completion Oct 23, 2025
Drug: Asundexian (BAY2433334); Placebo · For: Prevention of Ischemic Stroke; Acute Non-cardioembolic Ischemic Stroke; High-risk Transient Ischemic Attack
Sites: Fairhope, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 741 sites in all
- A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06065540 · 2,734 participants · Start Sep 27, 2023 · Primary completion Nov 19, 2025
Drug: Cagrilintide; Semaglutide and 2 more · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Pelham, Alabama; Phoenix, Arizona · 405 sites in all
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07216482 · 996 participants · Start Nov 11, 2025 · Primary completion Aug 3, 2026
Drug: Enlicitide; Rosuvastatin and 2 more · For: Hyperlipidemia
Sites: Birmingham, Alabama; Foley, Alabama; Phoenix, Arizona · 87 sites in all
- IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07473960 · 198 participants · Start Apr 1, 2026 · Primary completion Aug 26, 2026
Drug: IBI306; placebo and 2 more · For: Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Sites: Beijing, China
- Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06588504 · 38 participants · Start Sep 10, 2024 · Primary completion Jul 20, 2025
Drug: Dasiglucagon; Glucagon · For: Diabetes Mellitus, Type 1
Sites: Fukuoka, Japan
- The Efficacy and Safety of DLBS3233 in Adults With PrediabetesPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT07937449 · 120 participants · Start Jul 7, 2025 · Primary completion Oct 15, 2026
Drug: DLBS3233; Metformin XR · For: Prediabetes
Sites: Surabaya, Indonesia; Jakarta, Indonesia
- A Study of BGM0504 in Participants With Type 2 DiabetesPivotal-lookingCompleted
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT06716216 · 553 participants · Start Jan 13, 2025 · Primary completion Aug 25, 2026
Drug: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC and 1 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Beijing, China
- A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePivotal-lookingCompleted
BrightGene Bio-Medical Technology Co., Ltd.Industry
NCT06716203 · 227 participants · Start Jan 3, 2025 · Primary completion Aug 13, 2026
Drug: Drug: 5 mg BGM0504 Administered SC; Drug: : 10 mg BGM0504 Administered SC and 1 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Beijing, China
- Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03850782 · 515 participants · Start Feb 28, 2019 · Primary completion Aug 8, 2025
Drug: Bimatoprost (SR) · For: Open-Angle Glaucoma; Ocular Hypertension
Sites: Sun City, Arizona; Huntington Beach, California; Irvine, California · 108 sites in all
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsPivotal-lookingCompleted
Gan & Lee Pharmaceuticals.Industry
NCT06728124 · 640 participants · Start Dec 30, 2024 · Primary completion Mar 26, 2026
Drug: GZR18 · For: Obesity/Overweight
Sites: Beijing, China
- EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayPivotal-lookingCompleted
Rhythm Pharmaceuticals, Inc.Industry
NCT05093634 · 296 participants · Start Apr 26, 2022 · Primary completion Dec 19, 2025
Drug: Setmelanotide; Placebo · For: Obesity; Genetic Obesity
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 66 sites in all
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusPivotal-lookingCompleted
Gan & Lee Pharmaceuticals.Industry
NCT06778967 · 1,133 participants · Start Feb 13, 2025 · Primary completion Sep 18, 2026
Drug: GZR18; semaglutide · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Tianjin, China
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExercisePivotal-lookingCompleted
Gan & Lee Pharmaceuticals.Industry
NCT06777238 · 274 participants · Start Feb 24, 2025 · Primary completion Jul 30, 2026
Drug: GZR18; Placebo · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Beijing, China
- Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossPivotal-lookingCompleted
Gan & Lee Pharmaceuticals.Industry
NCT07292441 · 224 participants · Start Jan 22, 2026 · Primary completion Sep 22, 2026
Drug: GZR18 injection · For: Overweight or Obesity
Sites: Beijing, China
- SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)Pivotal-lookingCompleted
PolarityTEIndustry
NCT06140303 · 120 participants · Start Feb 22, 2024 · Primary completion Jan 30, 2026
Drug: SkinTE · For: Diabetic Foot
Sites: Mesa, Arizona; Castro Valley, California; Fresno, California · 23 sites in all
- Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) ProtocolPivotal-lookingCompleted
CellTrans Inc.Industry
NCT00679042 · 21 participants · Start Sep 5, 2007 · Primary completion Jul 19, 2017
Drug: Islets of Langerhans transplantation · For: Type 1 Diabetes Mellitus
Sites: Chicago, Illinois
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06034743 · 796 participants · Start Nov 22, 2023 · Primary completion May 21, 2025
Drug: Baxdrostat; Placebo · For: Uncontrolled Hypertension; Resistant Hypertension
Sites: Saraland, Alabama; Scottsdale, Arizona; Sun City West, Arizona · 263 sites in all
- Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04916470 · 617 participants · Start Jun 15, 2021 · Primary completion Oct 11, 2023
Drug: Semaglutide; Placebo (Semaglutide) · For: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Sites: Fairhope, Alabama; Mobile, Alabama; Beverly Hills, California · 180 sites in all
- A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 DiabetesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05901831 · 242 participants · Start Feb 26, 2024 · Primary completion Aug 20, 2025
Drug: Finerenone · For: Chronic Kidney Disease; Type 1 Diabetes Mellitus
Sites: Surprise, Arizona; Stanford, California; Vallejo, California · 79 sites in all
- Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C ReductionPivotal-lookingCompleted
LIB Therapeutics LLCIndustry
NCT04797104 · 478 participants · Start Apr 22, 2021 · Primary completion Jul 30, 2023
Drug: lerodalcibep · For: Heterozygous Familial Hypercholesterolemia
Sites: Cincinnati, Ohio; Jerusalem, Israel; Petah Tikva, Israel · 7 sites in all
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06534411 · 1,023 participants · Start Nov 5, 2024 · Primary completion Jun 2, 2026
Drug: Cagrilintide; Semaglutide and 1 more · For: Diabetes Mellitus, Type 2
Sites: Pelham, Alabama; Phoenix, Arizona; Tucson, Arizona · 163 sites in all
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06221969 · 1,024 participants · Start Jan 16, 2024 · Primary completion Mar 4, 2026
Drug: Cagrilintide; Semaglutide and 1 more · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 197 sites in all
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06192108 · 962 participants · Start Jan 10, 2024 · Primary completion Sep 26, 2025
Drug: Orforglipron; Dapagliflozin · For: Type 2 Diabetes
Sites: Canoga Park, California; Long Beach, California; Los Alamitos, California · 74 sites in all
- A Study of BGM0504 Injection in Participants With Obesity or OverweightPivotal-lookingCompleted
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.Industry
NCT06704581 · 652 participants · Start Oct 29, 2024 · Primary completion Mar 17, 2026
Drug: 5 mg BGM0504 injection; 10 mg BGM0504 injection administered subcutaneously (SC) once a week and 2 more · For: Overweight or Obesity
Sites: Beijing, China
- Open-Label Extension Study of DCCR in Patients With Prader-Willi SyndromePivotal-lookingCompleted
Soleno Therapeutics, Inc.Industry
NCT05701774 · 77 participants · Start Jan 31, 2023 · Primary completion Jan 12, 2026
Drug: DCCR · For: Prader-Willi Syndrome
Sites: Orange, California; Palo Alto, California; San Diego, California · 22 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.